[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563968":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":34,"collaborators":36,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":10,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"CerbaXpert","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":10},"Infected patients with hepatitis C virus",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Sabrina Kali, Dr","CONTACT","33762376831","skali@cerbaresearch.com",[18],{"facility":19,"status":10,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Cerba Xpert","Frépillon","Île-de-France Region","95000","France","FR",{"type":26,"coordinates":27},"Point",[28,29],2.20528,49.05216,{"lat":29,"lon":28},[32],{"name":33,"role":14,"phone":15,"phoneExt":10,"email":16},"Sabrina Kali, Dr.",{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[37],{"name":38,"class":39},"Bioneer Corporation","UNKNOWN","100563968","accupower--hcv-performance-evaluation-quant-kit-bioneer-existationfa-96384-100563968",false,"NCT06623058","Accupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96\u002F384","BIOPERF-HCV","Inclusion Criteria:\n\nThe patient to be included in this study must be able to understand the purpose of the research, in order to to give free and informed consent.\n\n* Subject aged over 18\n* Subject presenting at the investigation center and meeting one of these two criteria:\n\n  * Subject presenting with a prescription for HCV viral load determination\n  * Subject whose HCV infection is previously confirmed by CE marked tests.\n* Subject capable of understanding the purpose of the research having given express free and informed consent\n* Subject affiliated to or beneficiary of a social security system\n\nExclusion Criteria:\n\nProtected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial decision or administrative Subject participating in a clinical study\u002Freceiving investigational treatment\n\n\\-","ALL","18 Years",{"count":50,"type":51},45,"ESTIMATED","OBSERVATIONAL","As part of the CE marking of a hepatitis C diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE 2017\u002F746).\n\nCerba Xpert CRO of the Cerba Healthcare group promoted this performance study by setting up a prospective collection of blood samples from patients suffering from the virus hepatitis C and whose viral load is positive. This prospective collection will be carried out in 4 laboratories of the Cerba Healthcare group.",[55],"HEPATITIS C (HCV)","NOT_YET_RECRUITING","2024-10-02",{"date":59,"type":60},"2024-10-03","ACTUAL",{"date":62,"type":51},"2024-10-01",{"date":64,"type":51},"2025-05-30",{"name":5,"class":6},1]